← Back to Search

Checkpoint Inhibitor

Paclitaxel for Non-Small Cell Lung Cancer (TOP1705 Trial)

Phase 2
Waitlist Available
Research Sponsored by Jeffrey Clarke
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
A concurrent diagnosis of a separate malignancy is allowed if clinically stable and does not require tumor-directed therapy.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 4 years
Awards & highlights

TOP1705 Trial Summary

This trial will test the safety and effectiveness of two immunotherapy drugs, nivolumab and ipilimumab, when given with the chemotherapy drug paclitaxel to people with lung cancer that has not been treated before.

Eligible Conditions
  • Non-Small Cell Lung Cancer

TOP1705 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
If you have another type of cancer that is not actively growing and does not need treatment, you can still participate in the trial.

TOP1705 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Progression-free survival (PFS) as determined by the investigator using Response Evaluation Criteria In Solid Tumors RECIST 1.1 (brand name) or death, whichever occurs first
Secondary outcome measures
Description of the safety and adverse events of the combination nivolumab, ipilimumab, and paclitaxel in untreated, metastatic NSCLC.
Estimate the overall response rate with the study combination.

TOP1705 Trial Design

1Treatment groups
Experimental Treatment
Group I: nivolumab, ipilimumab and paclitaxelExperimental Treatment3 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Paclitaxel
2011
Completed Phase 4
~5380
Ipilimumab
2014
Completed Phase 3
~2640
Nivolumab
2014
Completed Phase 3
~4750

Find a Location

Who is running the clinical trial?

Jeffrey ClarkeLead Sponsor
3 Previous Clinical Trials
96 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does Nivolumab have the FDA's official stamp of approval?

"Nivolumab's safety is estimated to be a 2. This is due to it being in Phase 2 trials, so while there is evidence that it won't create too many adverse effects, efficacy has yet to be studied."

Answered by AI

Nivolumab is most commonly associated with which type of illness?

"Nivolumab can be used as an immunotherapy treatment for patients with unresectable melanoma, squamous cell carcinoma, and those at a high risk of cancer recurrence."

Answered by AI

What is the existing research on Nivolumab's efficacy?

"As of now, there are 1623 ongoing clinical trials researching Nivolumab. Out of these studies, 309 are in Phase 3. Most studies for Nivolumab are based in Shanghai; however, there are a total of 83232 locations conducting research on this medication."

Answered by AI

How many people are enrolling in this clinical trial?

"This particular study is no longer recruiting patients. It was initially posted on October 2nd, 2018 and was edited for the last time on April 22nd, 2022. For those still searching for clinical trials to participate in, there are currently 2002 trials for lung cancer and 1623 studies involving Nivolumab that are actively enrolling patients."

Answered by AI

Are people still being signed up for this experiment?

"Unfortunately, this particular study is not recruiting candidates at the moment. The listing on clinicaltrials.gov indicates that it was originally posted on October 2nd 2018 and last updated on April 22nd 2022. With that said, there are 3,625 other trials actively looking for patients right now."

Answered by AI
~7 spots leftby Mar 2025